SCHEMBL728782

SCHEMBL728782

O[C@H]1CC2CCN1CC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL72375 1.00
SCHEMBL731350 1.00
Hydrochloric Acid SCHEMBL4090424 0.97 GAA (0.32)
Hydrochloric Acid SCHEMBL27676966 0.97 GAA (0.32)
SCHEMBL2336833 0.82
SCHEMBL10401754 0.80 POLB (0.32)
SCHEMBL11350359 0.71
SCHEMBL6152816 0.69
SCHEMBL5180410 0.69
SCHEMBL4279010 0.67 SLC18A3 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-6056830-A None JP disclosed
US-12527776-B2 Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) GENZYME CORPORATION (US) 2026-01-20 US disclosed
EP-4626424-A1 VENGLUSTAT IN COMBINATION WITH A STRONG OR MODERATE INHIBITOR OF CYP3A4 GENZYME CORPORATION (US) 2025-10-08 EP disclosed
EP-3920912-B1 TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS) GENZYME CORP (US) 2025-06-11 EP disclosed
US-12083115-B2 Methods for treating neurological symptoms associated with lysosomal storage diseases GENZYME CORPORATION (US) 2024-09-10 US disclosed
WO-2024116127-A1 VENGLUSTAT IN COMBINATION WITH A STRONG OR MODERATE INHIBITOR OF CYP3A4 GENZYME CORPORATION (US) 2024-06-06 WO disclosed
EP-4349408-A2 METHODS FOR TREATING PROTEINOPATHIES Genzyme Corporation (US) 2024-04-10 EP disclosed
EP-3267983-B1 METHODS FOR TREATING PROTEINOPATHIES GENZYME CORP (US) 2023-12-20 EP disclosed
EP-3514157-B1 METHOD OF PREPARING GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2023-09-06 EP disclosed
US-20230118142-A1 AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE UCL BUSINESS LTD (GB) 2023-04-20 US disclosed
US-5888804-A SIMPLE AND EFFICIENT BIOSYNTHESIS BY INCUBATING MICROORGANISM WITB QUINUCLIDINONE, RECOVERING OR HARVESTING PRODUCT DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1999-03-30 US disclosed
EP-0863212-A2 Processes for production of optical active quinuclidinol Daicel Chemical Industries, Ltd. (JP) 1998-09-09 EP disclosed
EP-0838448-A1 Process for the separation of a mixture of enantiomers DSM N.V. (NL) 1998-04-29 EP disclosed
US-5637722-A ALKYLATION OF NUCLEOPHILE WITH ALKYL PROPARGYL XANTHATE RHONE-POULENC CHIMIE (FR) 1997-06-10 US disclosed
US-5569447-A TOMOGRAPHIC IMAGING AGENTS THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1996-10-29 US disclosed
US-5387409-A Diagnostic imaging agents, e.g. hypoxic tissue; radiotherapy; kits BRACCO INTERNATIONAL B.V. (NL) 1995-02-07 US disclosed
JP-H0656830-A METHOD FOR ENANTIOMERICALLY ENRICHING (R,S)-3-QUINUCLIDINOL BEND RES INC 1994-03-01 JP disclosed
EP-0577253-A2 Enantiomeric enrichment of (R,S)-3-quinuclidinol BEND RESEARCH, INC. (US) 1994-01-05 EP disclosed
US-5215918-A Acid anhydride esterification; preferential enzymatic hydrolysis with a subtilisin protease BEND RESEARCH, INC. (US) 1993-06-01 US disclosed
EP-0441491-A1 Boronic acid adducts of rhenium dioxime and technetium-99M dioxime complexes containing a biochemically active group BRACCO INTERNATIONAL B.V. (NL) 1991-08-14 EP disclosed